Podcasts about Hologic

Anyone who was in the LevFin market in 2022 may remember banks using term loan As to fill the financing gap when rising interest rates disrupted the syndicated loan market. That instrument has made a comeback — except this time, the TLA is no longer a back-up, but a tool to get larger financings done.In this episode, Cloud 9fin deputy LevFin editor Sasha Padbidri sat down with reporter Yiwen Lu and senior reporter Sunny Oh, to discuss the resurgence of the so-called pro-rata market.We broke down the key features of TLAs, how banks use them to differentiate themselves from direct lenders, and the evolving lender base of TLAs. We also discussed how it played out in recent jumbo buyouts, including Hologic.Have any questions? Send us a note at podcast@9fin.com. You can also check out our feature on TLA here. Thanks for listening!

Ever get your blood work back and think… okay but what does any of this actually mean?? This episode is for the woman who wants to understand her body instead of just reacting when something feels off. A recent 2024 Hologic x Gallup survey found that nearly half of women have skipped or delayed a health screening a doctor recommended. Not because they don't care, but because of things like time constraints, cost, anxiety around tests, or not thinking a screening applies to them. In this episode, we're breaking down a huge part of screenings and prevention: blood tests. I'm walking you through 10 blood tests that can reveal major health clues, what they actually tell you, and how knowing your numbers can help you feel more in control of your health — not stressed by it. Her Side by Flourish Heights was made for women, by women. To be empowered in health starts with a true connection with your body. Join Valerie Agyeman, a women's health dietitian and journalist as she explores overlooked women's health conversations, blending expert insight with real stories around periods, hormones, nutrition, and body awareness.  Stay Connected: Is there a topic you'd like covered on the podcast? Submit it to hello@flourishheights.com Subscribe to our quarterly newsletters: Flourish Heights Newsletter Visit our website + nutrition blog: www.flourishheights.com Resources: Why US Women Miss Critical Health Screenings: https://hologic.womenshealthindex.com/sites/default/files/2024-07/Hologic_US_Mini-Report_7.8.24.pdf Follow us on social media: Instagram: @flourishheights / Women's Health Hub: @hersidebyfh / @valerieagyeman Youtube channel: https://www.youtube.com/@flourishheights Want to support this podcast? Leave a rating, write a review and share! Thank you!

She nearly quit tennis last year.Seven surgeries, constant setbacks, and a body few doctors understood.Today, Francesca Jones reveals how she fought through doubt, pain, and pressure to break into the Top 100 — and what she's learned along the way.⏱️ TIMESTAMPS / CHAPTERS00:00 – “This year was supposed to be my last…” Career crossroads, feeling stuck, and finding unexpected freedom.03:10 – Moving to Spain alone at 10 to chase a dream Early sacrifices, school-life balance, and building identity away from tennis.06:20 – Toxic coaches, abuse of power & lack of safeguarding in tennis Francesca opens up about dangerous dynamics young players face. Episode Francesca Jones12:40 – Becoming the CEO of her own career at 16 Learning decision-making, emotional intelligence, and firing the wrong people.21:00 – Living with a rare syndrome & surgeries no doctor understood How unique biomechanics shaped her challenges and mindset.27:00 – The brutal truth: she had to stop tennis to rebuild her body Three-month physical reset, strength work, and realizing the sport changed.31:30 – “I'll die on the court if I have to” — her mentality explained Obsession, overtraining, collapsing in matches, and learning limits.44:00 – The moment she almost quit tennis forever Doubt, burnout, Patagonia reflections, and the conversation that saved her.52:00 – Breaking Top 100 & what's next Long-term goals, redefining success, and chasing stability for the first time.If you enjoyed this conversation, hit LIKE, SUBSCRIBE, and drop a comment telling us your favorite insight from Francesca.Your support helps us bring more raw, honest stories from the world's best players.This episode is brought to you by Hologic, a global leader in women's health — dedicated to early detection, innovation, and helping women live healthier, longer lives. Hosted on Acast. See acast.com/privacy for more information.

Solana Cirstea spent 20 years chasing the biggest dreams in tennis — No.1, Grand Slams, perfection.Now, she opens up about pressure, regret, joy, and why 2026 will be her final year…One of the rawest mindset conversations ever on Tennis Insider Club.⏱️ TIMESTAMPS / CHAPTERS01:40 – How her father pushed her into tennis from age 405:10 – Becoming a top junior and breaking into WTA at 1607:20 – The crash after the French Open quarterfinal run10:00 – Struggling with expectations & “learning how to lose”11:50 – The injury that changed everything at 2513:10 – Shifting from results obsession to joy & process17:00 – Why knowing “why you play” changes everything23:00 – Handling wins/losses: staying emotionally steady25:00 – Discovering balance, friendships & life outside tennis33:30 – Playing through pain & the mental toll35:00 – Why 2026 will be her final season37:00 – Making peace with not becoming No.143:00 – “What you're complaining about is someone's dream”54:00 – Juniors vs pros: the myth of early success56:00 – School, development & advice for parents58:30 – Generational changes on tour01:02:00 – How the game evolved & the new WTA levelIf you enjoyed this episode, subscribe, drop a like, and share your thoughts in the comments.Which part of Sorana's story resonated the most with you?This episode is presented in partnership with Hologic, global leader in women's health. Hosted on Acast. See acast.com/privacy for more information.

At just 29, Garbiñe Muguruza—2x Grand Slam Champion and former World No.1—made the shocking decision to step away from tennis. In this raw, emotional conversation, she opens up to Caroline Garcia and Borja Durán about pressure, burnout, family sacrifice, and finding peace beyond trophies.Key Moments:01:00 – Growing Up in Venezuela & Family Sacrifice06:00 – Strict Parenting and Losing Childhood Innocence12:00 – Breakthrough Moment at Miami Open15:00 – Winning Roland Garros Against Serena Williams19:30 – “No One Cares About the Finalist”23:00 – The Dark Side of Perfectionism33:00 – After the WTA Finals: Relief, Burnout, and Self-Discovery37:00 – Making Peace With Stepping Away From Tennis45:00 – Life After Tennis: Becoming WTA Finals Tournament Director49:00 – Advice to Her Younger SelfIf you enjoyed this conversation, don't forget to subscribe, like, and comment your favorite moment! It really helps us bring you more authentic tennis stories.This episode is brought to you by Hologic. Hosted on Acast. See acast.com/privacy for more information.

Muchas noticias empresariales. La cosecha de resultados trae algo de aliento con General Motors. El fabricante eleva sus perspectivas financieras para el año y baja ligeramente su estimación para el impacto de los aranceles. Sube 14% y da impulso a un sector de consumo discrecional, en el que caen las acciones de Tesla. Coca-Cola sube un 4%. Sus cuentas baten expectativas gracias a la resistente demanda de sus bebidas sin azúcar en Estados Unidos, y de refrescos a nivel internacional, a pesar de la cautela del gasto en todo el mundo. Se mueven también con resultados y previsiones empresas de defensa como GE Aerospace, Lockheed Martin y RTX. Luego hay fusiones y adquisiciones. Confirmadas. La de los fondos Blackstone y TPG por Hologic, empresa de dispositivos médicos. Pagan 18.300 millones. Y por confirmar. En medios. Warner Bros Discovery considera su venta. El todo o por partes. Estarían detrás Netflix y Comcast. WBD es propietaria de CNN, HBO Max y la franquicia de "Harry Potter". Analizamos el mercado con César Sánchez-Grande. Le preguntamos por Enagas, Vidrala y Ebro Foods. Y, en Gestión del Patrimonio, Rafael Luque, CEO de Ariema. Asesora el fondo Renta 4 Megatendencias Ariema, el primero del mundo especializado en hidrógeno.

Amazon Web Services suffered an overnight outage disrupting sites including Disney+, Perplexity, and Coinbase. Apple's newest generation of iPhones has outsold previous models in its first 10 days on the market, China is accusing the U.S. of a hacking campaign, shares of Hologic were boosted by reports of a potential Blackstone and TPG takeover, and proxy advisory ISS is recommending Tesla shareholders vote against Elon Musk's $1 trillion pay plan. Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

S&P futures are up +0.4% and pointing to a higher open. Asian equities began the week's trading on a high note, with Japan's Nikkei surging over +3% as political clarity boosted sentiment. Hong Kong's Hang Seng also gained +2.4%, led by sharp advances in big tech. European markets are also higher in early trade as gains are being supported by easing US-China tensions and strong momentum from Asian markets. However, the French CAC is lagging slightly, following S&P's decision to downgrade France's credit rating late last week. Companies Mentioned: Tesla, Hologic, The Cooper Cos, Boeing

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Merger Monday mit Übernahmen von: Exklusiv-Club Soho House, Dayforce, Amphenol kauft Kabelhersteller für Rüstungsboom und Berlusconi failed bei Pro7. Den Wind- und Solaranbietern geht's sonnig und Novo Nordisk gewinnt sogar mal gegen Elli Lilly. Hologic (WKN: 879100) setzt sich für die Gesundheit von Frauen ein und das tut nicht nur dem Gewissen, sondern auch dem Geldbeutel gut. Blue OWL (WKN: A2QPLU) produziert Milliardäre mit Privatkrediten an KI-Unternehmen Diesen Podcast vom 19.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Today's guest is Tim Burge, Director at Aquant. Aquant is an AI platform built for service teams that maintain and repair complex equipment. It gives clear, accurate answers to service questions — from basic fixes to deep diagnostics — so field techs, call centers, managers, and customers can get to solutions faster. Used by top manufacturers like Siemens and Hologic, Aquant helps reduce downtime, lower service costs, and boost customer satisfaction. Tim joins Emerj Editorial Director Matthew DeMello for today's conversation to discuss how manufacturing leaders are reevaluating their AI deployment strategies across field service and operations. As the dust settles on the generative AI hype cycle, organizations are moving past the build-versus-buy binary and embracing hybrid approaches. Tim explains why service departments in particular require a specialized lens for AI implementation and shares how leaders can optimize time-to-value, improve data quality, and drive adoption across legacy environments. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Aquant. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Hier geht's zur Warteliste für das Kinderdepot.  Hier erfahrt ihr, wie ihr euch die 25 € Prämie sichern könnt. EU schnell + Verbraucher happy = Rekordhoch. SM & YG Ent. steigen dank Ende von K-Pop-Verbot. Tesla x Musk. Toyota x Software. Xiaomi x Wachstum. Pinduoduo x Problem. BAT - ITC. Salesforce + Informatica. Hologic - Übernahme. Southwest - Freigepäck. Planet Fitness (WKN: A14U2K) und der ewige Kampf gegen die Fitness. Bilfinger (WKN: 590900) hat sich in drei Jahren verdreifacht. Was steckt dahinter? Diesen Podcast vom 28.05.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

In the latest episode of the SALT Shaker Podcast, Eversheds Sutherland Counsel Jeremy Gove and Chelsea Marmor explore a new, concise podcast format that provides updates on recent noteworthy cases. Jeremy and Chelsea examine a New Hampshire court's decision in Hologic, Inc. v. Stepp, covering the facts, the court's holding, the analysis, and the case's practical implications. They wrap up the episode with a new segment, asking “either/or” – do you prefer the vernal equinox or autumn equinox? You can read our summary of Hologic, Inc. v. Stepp here. For questions or comments, email SALTonline@eversheds-sutherland.com. Subscribe to receive regular updates hosted on the SALT Shaker blog.

LIVE from Transform 2025 in Las Vegas! Amira Barger is an award-winning Executive Vice President of Communications and Head of DEI Advisory at Edelman, providing senior reputation management and polycultural counsel to clients across the globe. Recently named Woman of the Year by Women Health Care Executives, Top 100 Executives by Involve People, Top CMOs of 2024 by the CMO Alliance, Top 50 Global DEI Professionals by OnConferences, Top 100 People Leaders by Mogul, Fearlessly Authentic Leader by Leaderology, and 30 under 40 in Healthcare Innovation by Business Insider – Amira is a scholar, practitioner and thought leader who brings more than 20 years of experience in strategic communications that reach stakeholders, mobilize the community and inspire action. Amira has global experience in pharma/healthcare communications, corporate branding, web and social media, M&A experience, media relations, team management, sustainability/social impact, reputation management, and DEI. Throughout her career, Amira has utilized these competency areas for clients such as: CVS Health, Eli Lilly, Walgreens, Hologic, Genentech, Pfizer, GSK/Haleon, BMS, Zoetis, Alkermes, Regeneron, Amgen, Medtronic, Children's Miracle Network, Kaiser Permanente, First 5 Los Angeles, Covered California, Centers for Disease Control and Prevention, FEMA, and California Community Colleges. Adam and Amira discuss: - How does “niceness” in workplace culture hold back real DEI progress, and what should leaders do instead? - Challenging Workplace Norms to Advance DEI and Justice - Empowering Women in Leadership - Valuing the Whole Human - "How can leaders move beyond surface-level well-being initiatives to truly create workplaces that honor employees as whole humans, not just workers? Connect with Amira: https://www.linkedin.com/in/amirabarger/ Live from Transform 2025, we're bringing you an exclusive podcast series packed with insights from some of the brightest minds in hiring, talent strategy, and workforce transformation! In this series, we've got incredible guests from Okta, Tubi, Edelman, Greenhouse, Findem, and more, sharing how top organizations are rethinking hiring, culture, and talent acquisition in today's fast-changing world. Greenhouse combines a structured, data-driven hiring approach with AI-embedded workflows that empower recruiters to focus on strategic, high-impact work. From sourcing top talent to personalizing the candidate experience, Greenhouse streamlines and optimizes the entire hiring process. This ensures that every hire is the right hire—eliminating bias, creating fairness, and helping teams make smarter, faster decisions. Over 7,500 companies, including HubSpot, Duolingo, and J.D. Power, trust Greenhouse to build better teams and turn talent into a strategic advantage. Want to learn how today's top companies are winning the talent game? Tune in now and visit Greenhouse.com to transform the way you hire. Thanks for listening. Please follow us on Instagram @NHPTalent and X @AdamJPosner. Visit www.thePOZcast.com for all episodes

Welcome to the Health Marketing Collective, where strong leadership meets marketing excellence. Today, in today's episode, Julia Steele Rodriguez joins us to discuss the critical role of Key Opinion Leaders (KOLs) in healthcare marketing. Julia, who led key teams in the breast and skeletal health division at Hologic, shares her vast experience in building and nurturing KOL programs across various med device companies. Throughout the episode, host Sara Payne and Julia discuss the intricacies of engaging KOLs effectively to enhance brand trust, communicate complex information, and foster both clinician and patient education. Together, they explore how to define what a KOL means within an organization, strategies for identifying and selecting the right KOLs, and the dynamics that make for a successful, long-term KOL partnership. Thank you for being part of the Health Marketing Collective, where strong leadership meets marketing excellence. The future of healthcare depends on it. Key Takeaways: Defining KOLs: Julia emphasizes the necessity of having a clear, shared definition of a KOL within an organization. Aligning on this definition ensures that everyone understands that KOLs are influential figures who can impact healthcare professionals and patients beyond their own organization. Identifying the Right KOLs: Strategies include researching publications, conferences, and professional societies to find those who are influential in their field. Julia stresses the importance of considering both objective data and subjective elements like personality and organizational fit. Fostering Long-Term Relationships: For KOL partnerships to be successful, they must be mutually beneficial. This involves understanding the KOLs' interests and ensuring they find value in the partnership, be it career development or influencing market innovations. Challenges in KOL Programs: Successful KOL partnerships require seamless internal processes, such as contracting and communication, as well as clear expectation setting and regular updates to maintain engagement and trust. Impact of KOLs on Marketing Strategy: Effective KOL partnerships can significantly influence healthcare marketing strategies, as evidenced by Hologic's success in advancing three-dimensional mammography as the standard of care. KOLs can powerfully advocate for policies, enhancing both market presence and healthcare access. This insightful conversation with Julia offers valuable perspectives on integrating KOLs into healthcare marketing efforts, underscoring their role in advancing organizational objectives and healthcare outcomes. [embed]https://youtu.be/oaAmR-Mk3zE[/embed]

Women's health remains a critical issue globally, with alarming disparities in access and outcomes. A new survey from Hologic and Gallup reveals that while nearly 90% of women recognize the importance of health screenings, less than half undergo them consistently due to barriers like cost, time, and anxiety. The stakes are particularly high in underserved communities, where delayed diagnoses can lead to advanced cases of conditions like cervical and breast cancer.What can be done to ensure equitable access to healthcare for all women, especially in marginalized and rural areas? Can artificial intelligence revolutionize screening and diagnostics to save lives?On I Don't Care, host Dr Kevin Stevenson has a chat with Mia Keeys, Director of Global Health and Innovation at Hologic. Together, they delve into the intersection of equity, technology, and advocacy in women's health.Key Takeaways:Barriers to Women's Health Access: Structural challenges like transportation, affordability, and cultural trust hinder consistent screenings, despite widespread recognition of their importance.AI's Role in Healthcare: AI technologies, such as Hologic's digital cytology for cervical health, enhance efficiency in diagnostics and provider workflows, addressing burnout and improving care.Advocacy for Policy Change: Maintaining healthcare access through programs like the Affordable Care Act and expanding support for underserved areas are pivotal in improving outcomes.Dr. Mia Keeys is a global health expert and director at Hologic, focusing on women's health innovation and equity. A former chief of staff for Congresswoman Robin Kelly, she has spearheaded health equity initiatives in Congress, at the American Medical Association, and abroad. Her academic pursuits include health policy and artificial intelligence, with field experience in countries like Indonesia and South Africa.

Michael Quick is a cytologost currently serving as the VP of R&D and Innovation for Cytology and Oncology at Hologic and the 2024 DPA President. Mike shares his background as a cytologist and how it led to a career focused on innovation in the digital pathology industry. Hologic has grown into the digital pathology and laboratory industry, and we discuss motivations for expansion of a large company into new areas of medicine. Finally, we feature an interview from Pathology Visions 2024 where Mike reflects on the conference and accomplishments as DPA President.A forum to engage with the hosts and other listeners has been launched on the DPA website www.digitalpathologyassociation.org. DPA members may login to the DPA Collaborate hub (under the Resources tab) and join the Beyond The Scope community. All listeners are encouraged to use this forum to suggest future topics and guests, submit questions and corrections, and provide general feedback.

Approximately 50,000 East and Gulf Coast port workers began a strike last night. Investor and Boston Celtics owner Glenn Hutchins discusses his perspective on the strength of the economy and the possibility of a soft landing for the Fed. Next, Steve MacMillan, CEO of diagnostic maker Hologic, talks about breast cancer awareness and how his company is using AI to help detect cancer. Plus, the death toll from Hurricane Helene has reached 130 people and legendary baseball player Pete Rose has died at age 83. Glenn Hutchins - 12:18Steve Macmillan - 27:19 In this episode:Becky Quick, @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinZach Vallese, @zachvallese

The thought of your teen making a life-altering mistake because of alcohol is terrifying. We know that underage drinking can lead to devastating consequences, from impaired driving accidents to the dangerous combination of alcohol with other drugs. But here's the thing—these tragedies are entirely preventable. To help us navigate this tough topic, I'm joined by Stacey D. Stewart, CEO of Mothers Against Drunk Driving (MADD). Stacey is going to share how we, as parents, can address this fear, take action, and keep our teens safe from the dangers of drinking.   Key Takeaways ➡️ Underage drinking and impaired driving are still major issues with devastating consequences. ➡️ Parents play a crucial role in preventing underage drinking and impaired driving by having open and ongoing conversations with their children. ➡️ Providing information and resources to children helps them make informed decisions and understand the dangers of alcohol and substance use. ➡️ Parents should model responsible behavior and seek help if their child is struggling with substance use. Meet Today's Guest: Stacey D. Stewart Stacey D. Stewart is the CEO of Mothers Against Drunk Driving (MADD).  For more than 25 years, Stacey has served in purpose-driven roles including President and CEO of the Fannie Mae Foundation, U.S. President and Executive Vice President for Community Impact Leadership and Learning at United Way Worldwide (UWW), and most recently the President and CEO of March of Dimes. Stewart is a graduate of the Ross School of Business at the University of Michigan where she earned an MBA in Finance and a Bachelor of Arts degree in Economics from Georgetown University and holds numerous honorary degrees. She has been a director on more than 40 non-profit boards, nationally, and in the Washington, D.C. Metropolitan Area.  Stewart also serves on the boards of Hologic, Inc., a medical technology company focused on women's health and PennyMac Mortgage Investment Trust, a residential real estate investment trust.  Stacey is a mother to two college-age daughters and resides in Bethesda, MD with her husband. Connect with Stacey Website | Instagram | Facebook | LinkedIn | X | YouTube | TikTok   Meet Your Host: Dr. Cam Cameron (Dr. Cam) Caswell, a.k.a. "The Teen Translator," gets it! As an Adolescent Psychologist & parent of a teen, she knows the struggles of navigating those tough years firsthand. As a private practitioner, TEDx speaker, podcast host, and author, she offers hope and practical strategies to help parents unlock their teen's confidence & resilience, build deeper, stronger connections with them, and foster a positive home environment. Listen to her podcast, "Parenting Teens with Dr. Cam," and follow her in Instagram @drcamcaswell for actionable advice. Connect with Dr. Cam Website | Instagram | TikTok | YouTube   Resources Mentioned in This Episode FREE QUIZ: Are You on the RIGHT Track With Your Teen? MADD's digital Power of Parents handbook Thanks so much for listening to our podcast! If you enjoyed this episode and think that others would appreciate the guidance and encouragement, please take a quick moment to rate and review. Reviews from my listeners are extremely valuable and greatly appreciated. Review on iTunes. Subscribe to the Podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on iTunes, YouTube, Spotify. You can also subscribe from the podcast app on your mobile device.   ABOUT THE SHOW: The 'Parenting Teens with Dr. Cam' Podcast: Your Guide to Navigating Adolescence Without the Drama. Hosted by Cameron (Dr. Cam) Caswell, an adolescent psychologist specializing in empowering parents and nurturing teen development. In each episode, she partners with a guest expert to deliver invaluable insights and practical advice for building a closer relationship with your teen & finding joy amidst the challenges Whether you're an experienced parent looking to enhance your teenager's mental well-being and strengthen your connection, or a newcomer to the world of adolescence, this podcast is a must-listen.    #ParentingTeens  #Podcast #teenagers #parentingpodcast #TeenMentalHealth #MentalHealthAwareness #drcamcaswell #theteentranslator #TeenSafety #UnderageDrinkingPrevention #MADD #TalkAboutAlcohol #ParentingSupport

Leslie Picker and Brian Sullivan tackle today's biggest Money Movers from the floor of the New York Stock Exchange. 

In this episode, Dr. Amy Brenner, a seasoned surgeon specializing in women's health treatments, sits down with Denise Lyon, an expert on the innovative Acessa procedure for fibroids. Together, they delve into the complexities of fibroids, discussing their impact on women's lives, symptoms, and treatment options. Key Talking Points: Understanding Fibroids: Denise Lyon explains that fibroids are benign tumors of the uterus, influenced primarily by estrogen. They can grow in different locations—inside the uterine cavity (submucosal), within the uterine wall (intramural), or outside the uterus (subserosal)—each location impacting symptoms differently. Prevalence and Impact: Up to 77% of women may develop fibroids, often leading to heavy bleeding (menorrhagia), pressure symptoms, pain, and other discomforts affecting daily life. Treatment Options: Dr. Amy Brenner outlines a range of treatments from conservative approaches to more invasive procedures like hysterectomy. They discuss the benefits of Acessa, a minimally invasive laparoscopic procedure designed to shrink fibroids without the need for major surgery. Acessa Procedure Explained: Densie and Dr. Brenner detail the Acessa procedure, highlighting its use of ultrasound to target and destroy fibroid tissue with minimal disruption. They compare it favorably to other treatments in terms of recovery time, pain management, and efficacy. Patient Considerations: The conversation covers why Acessa might be chosen over other methods, especially for patients with bulk symptoms or specific fibroid characteristics. Success and Recovery: They share data on Acessa's success rates, reduction in bleeding, and patient satisfaction, emphasizing its long-term benefits and quicker recovery compared to traditional surgeries. Patient Experience: Dr. Amy Brenner discusses what patients can expect post-procedure, including pain management, recovery timeline, and when they can anticipate relief from symptoms. Join Dr. Amy Brenner and Denise Lyon as they unpack the complexities of fibroids and explore how the Acessa procedure is reshaping treatment options for women seeking relief from this common condition. Learn about the Acessa Procedure in Cincinnati like and subscribe!  Instagram- https://www.instagram.com/amybrennermd/ Facebook- https://www.facebook.com/DoctorAmyBrenner YouTube- https://www.youtube.com/c/AmyBrennerMD Special Guest - Denise Lyon Denise Lyon is a market development specialist with Hologic, Inc., an innovative medical technology company dedicated to enhancing women's health and wellbeing. With a biology degree from Capital University and a surgical technology degree from Cincinnati State, Denise brings nearly nine years of experience at Hologic, having served in roles ranging from surgical medical science liaison to her current position. Before joining Hologic, Denise gained extensive experience as a surgical technologist at Good Samaritan Hospital. Her career is driven by a profound passion for women's health, advocating for increased education, innovation, and investment in the field.

In this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics. In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic's Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic's dedication to women's health and the critical role of AI in addressing the shortage of skilled cytologists, ensuring faster and more accurate diagnostics for patients worldwide. He also touches on the challenges and opportunities faced during the FDA approval process and the importance of early and collaborative engagement with regulatory bodies. We also hear from Dr. Wael Yared, Chief Technology Officer at Tecan, who highlights Tecan's contributions to cancer research and diagnostics. Dr. Yared elaborates on the company's innovations in liquid biopsy and solid tissue biopsy workflows, which leverage AI to streamline processes and reduce errors. He emphasizes the significance of partnerships in driving medical advancements and the role of AI in personalized medicine and multiomic capabilities. This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about Tecan visit, https://partnering.tecan.com/ Please subscribe to DeviceTalks AI on all major podcast channels and subscribe to DeviceTalks on YouTube to ensure you never miss an episode. Thank you for listening to DeviceTalks AI!

It's Episode 101 and the highlight is Tracy an Elisabeth's interview with Tracy Minutolo—Head of Operational Excellence at the technology health company Hologic. We'll find out how Tracey morphed from a microbiologist into a Lean Six Sigma Black Belt. For Hot Apps, we'll give you our take on a serious rival for ChatGPT—or a perfect companion for Google—or both. And then we'll dig into a question that came up recently about our negativity bias—is it a force for good or evil? In the meantime, fill that mug and get comfy! 0:00 - Intro 1:37 - What's on the menu? 2:23 - Hot Apps Perplexity 9:42 - Q&A Negative bias - a force for Good? 16:00 -Featured Guest Tracey Minutolo 38:48 - Upcoming Events Webinar: Good Data, Poor Data: Elevating Your Data Quality "5S Baby" Spoof Lean Rap Video Reveal Party Resources: Multiple-award-winning book, "Picture Yourself A Leader" Lean Parody Video, "Baby Got Tools!"  Thanks for Listening! Listen to more podcasts at JITCafe.com. Link to the video version of this podcast: https://youtu.be/vIUn3Sa2qTo Find us on: Apple Podcasts Podbean Spotify RSS Feed: https://feed.podbean.com/JITCafe/feed.xml 

Part 3 of 3. My guest for this week's episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

In this episode of Medsider Radio, we had an engaging conversation with Marissa Fayer, CEO of DeepLook Medical. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.   Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She's the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She's a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award. In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Marissa Fayer.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Welcome everyone to the weekly San Diego Tech News by Neal Bloom and Fred Grier from Fresh Brewed Tech. I'm Neal Bloom from Fresh Brewed Tech, the Tacos and Tech Podcast, and Interlock Capital. I'm Fred Grier, journalist and author of The Business of San Diego substack. I wrote about the tech industry for the San Diego Business Journal for two years. I covered the ins-and-outs of the startup world for much of that time, breaking news on IPOs, fundraising rounds, and M&A. Before we dive in, we wanted to ask our listeners and SD Tech fans to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup community. 2/13/2024 News More multi-billion $ biotech exits Inhibrx - $2.2B Axonics in OC - $3.7B Talked Ambrx for $2B already Tyra & many other post-IPO raises   $200M for Tyra Biosciences $150M for Kura Oncology   Eggscape Entertainment - $4.25M seed Trust & Will recent raise Touchdown Ventures, Erie Ventures, Comcasts' LIFT Labs Aptera - $33m in crowdfunding   New fund alert! TL Fund by Connect - $15m, all proceeds go back into the fund   Super Bowl ads In the past - Clickup, Hologic, Cue Cue Health - layoff 30% of workforce   Events - For full list - check The Social Coyote North County meetup debrief SD VC 2024 Outlook - Feb 13 AgX Hackathon March 7-9

Carl Quintanilla and Sara Eisen tackle today's biggest Money Movers from the floor of the New York Stock Exchange. 

The Hologic Global Women's Health Index is one of the most comprehensive initiatives measuring the state of health for 97% of the world's women and girls. Though the pandemic may be over, the Index reveals that women's health is no better now than it was at the height of it -- and in some cases, women's health is now worse. Laura Gillespie, vice president for Women's Health Initiatives at Hologic, joins the podcast to discuss women's testing for deadly diseases, their emotional health and their experiences across the world. “The Index findings make it exceedingly clear that it's time for world leaders to take a bolder stand for women and girls,” Gillespie says. “Women are the backbone of families, the backbone of communities and economies -- and investing in women's health benefits all of us.”

Schätzungen zufolge leiden bis zu einem Viertel aller Frauen unter einer starken, mitunter langanhaltenden Menstruationsblutung, einer Menorrhagie [1]. Die Patientinnen sind im Alltag häufig stark eingeschränkt. Über aktuelle Therapiemöglichkeiten für die Patientinnen berichtet unser Experte Prof. Dr. Becker.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 22, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. There are more funding raises in the news this week. The first one is from MedTrace, which raised $19 million for its PET-boosting technology. Fast Five hosts Sean Whooley and Danielle Kirsh go over what the funding will go toward and the technology they're developing. ProSomnus is raising $10 million for its CPAP alternative. Find out what the technology is and how optimistic executives are about the future of the technology. Whooley details a regulatory nod for Quantum Surgical's surgical robot in China. Hear about what the robot does, what kind of treatment it offers and what executives think about the regulatory nod. Medtronic Diabetes is having a good year – its Simplera CGM in InPen just won CE mark approval. Whooley and Kirsh discuss what technology and when Medtronic expects to launch the CGM. Hologic and Bayer have announced a partnership to improve mammography imaging. The Fast Five hosts go over the goal of the partnership and how the company plans to meet that goal.

Today on the podcast I am syncing up with WTA President, Micky Lawler.  As head of the Women's Tennis Association, the organization founded by Billie Jean King in 1973, Micky oversees the organization representing more than 1,600 athletes across 85 countries and hosting more than 50 annual events and four Grand Slams. It is the 50th Anniversary of the WTA and US Open this year and syncing up with Micky is an amazing way to get the ball rolling when it comes to the world of Tennis.  She is a true thought leader and game changer!  Micky was recently honored by Forbes on the 50 over 50 list as her work has been truly instrumental in the world of women's tennis and the WTA. She is responsible for expanding the WTA Tour in China and Asia more broadly. This expansion has included forging broadcast deals, setting record prize money and creating new tennis events for women in the sport. During our conversation, we talk about where her career in Tennis began and how she has played an integral role in the growth of Women's Tennis and the WTA over the years. We do a deep dive into the WTA partnerships and the role they play in expanding the sport and empowering athletes for success with tools for training, recovery, mental health, business and finance education  including most recent sponsorships with Hologic and Morgan Stanley as well as other partners SAP, Whoop, Modern Health.   I get behind the scenes intel on the ideation and production of Break Point, the amazing Tennis Docuseries on Netflix and how it came to fruition.  And of course, I get the scoop on the exercise and wellness fueling Micky for success as a busy executve, always on the move! About the WTA: Founded by Billie Jean King in 1973 on the principle of equal opportunity, the WTA is the global leader in women's professional sports. The WTA is one of the world's most recognizable and high-profile sports organizations, consisting of more than 1650 players representing approximately 85 nations, all competing to earn WTA rankings points and prestigious tournament titles. The WTA Tour comprises of over 50 events and four Grand Slams, spanning six continents and nearly 30 countries and regions with a global audience of over 700 million. The Tour culminates with the WTA Finals, honoring the season's top singles and doubles players based on the final standings of the Race to WTA Finals leaderboard. Further information on the WTA can be found at wtatennis.com. CONNECT WTA on Instagram, YouTube, and Facebook Marni On The Move Instagram, TikTok, LinkedIn, or YouTube Marni Salup on Instagram and Spotify SUBSCRIBE TO OUR NEWSLETTER Sign up for our weekly newsletter, The Download, for Marni on the Move updates, exclusive offers, invites to events, and exciting news! OFFERS AG1: DrinkAG1.com/MarniOnTheMove DeltaG: Get 20% off deltaG Ketones today at www.deltagketones.com use our code Marni20 SUPPORT THE PODCAST Leave us a review on Apple. It's easy, scroll through the episode list on your podcast app, click on five stars, click on leave a review, and share what you love about the conversations you're listening to. Tell your friends to what you love on social. Screenshot or share directly from our stories the episode you're listening to, tag us and the guests, and use our new Marni on the Move Giphy!

Earnings season continues in the medical device industry. Hologic posted its Q3 results this week, and it was a mixed bag. Investors and analysts have questions about future margins. Fast Five hosts Sean Whooley and Danielle Kirsh review the company's performance and the analysts' views.  The FDA recently granted expanded indication to Teleflex's QuikClot Control+ hemostatic device. The expanded indication may allow Teleflex to target new clinical applications. Find out what the expanded indication covers, how it increases the device's versatility in treating different patient populations, and what executives say.  Abbott FreeStyle Libre 3 reader is now available and is covered by Medicare. The Fast Five hosts discuss how the FreeStyle Libre 3 reader works and how it pairs with Abbott's latest continuous glucose monitoring sensor. Gain insights into Abbott's pipeline activity and plans for the second half of 2023. Integra Lifesciences plans to resume manufacturing at its Boston facility just two months after it voluntarily recalled all tissue-related products made at the plant. Whooley explains why the company stopped manufacturing and how it has addressed the problems since the recalls, including the measures taken to strengthen leadership and project management.  The FDA has labeled Baxter's recall of some infusion pumps as Class I, the most serious kind. Kirsh and Whooley go over the issues behind the recall, how many devices are included and what resolution the company is offering.  Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Ariel Sutton, general manager of Imperative Care's stroke business, joins us to explain why she swapped her medical school dreams for the opportunity to wear steel-toed boots and a hard hat as an engineer. Sutton ultimately would marry her love of medicine with her passion for engineering and built a career helping medical device companies of many sizes to build successful programs. Now she's leading one of the fastest growing neurovascular businesses in the industry. In her new role she's going to help guide Imperative Care's plans to target stroke from many different directions, including surgical robotics. Learn more about Imperative Care here. https://imperativecare.com/zoom-stroke-solution/ This week's episode is sponsored by DeviceTalks West. Registration opens later next week. Go to DeviceTalks.com. Co-hosts Chris Newmarker and Tom Salemi review this week's Newmarker's Newsmakers including iRhythm, Medtronic, Illumina, Hologic, Senseonics, and Know Labs. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast application.

Moon Surgical, a promising player in the field of surgical robotics, has successfully raised $55.4 million in funding to support the development of its surgical robot platform. This significant investment indicates growing confidence in Moon Surgical's technology and its potential to revolutionize surgical procedures. Fast Five hosts Sean Whooley and Danielle Kirsh discuss the company's technology and what those new funds are earmarked for.  In a creative and impactful move, Hologic has partnered with Eagles rookie Kelee Ringo and his mom to raise awareness about the importance of mammograms. This collaboration sheds light on the critical role of regular mammograms in the early detection and prevention of breast cancer. Whooley explains the details of the partnership, as well as the numerous other partnerships Hologic has engaged in to promote women's health and wellness. An independent study has provided further validation for Edwards' aortic valve with Resilia tissue. The study's findings underscore the potential of this technology to improve patient outcomes and contribute to the advancement of aortic valve therapies. Whooley details the study and the key findings in today's Fast Five episode.  Abbott has recently reported positive data for its TriClip Transcatheter Edge-to-Edge Repair (TEER) system. The positive data highlights the effectiveness and safety of the TriClip system, providing new hope for patients in need of mitral valve repair. Kirsh and Whooley explore the study's findings and how optimistic leaders at the company are. Precision Lens and its owner have been hit with a substantial $487 million judgment in a kickbacks case. This case highlights the importance of ethical business practices within the medical device industry. Whooley has all the details of the judgment and the judge's verdict on the case.  Check out the show notes at MassDevice.com/podcast.

In the Heroncode studio we are joined by the Managing Director, MEA at Hologic, Inc, Sarah Kaouache.Sarah Kaouache holds a doctorate in pharmacy and an MBA in healthcare strategy and marketing. She has built her career in the last 15 years in the healthcare industry within multinational companies both in the pharmaceutical and medical device sectors, such as Allergan, Cynosure, and most recently Hologic, a global medical device company championing women's health.She is an agile, resilient, and inclusive leader with proven success across various fields such as ophthalmology, transplants, dermatology and within diverse geographies managing Europe, Middle East and Africa. Her innate curiosity, passion for learning, and ability to overcome challenges have subsequently defined her life and career journey.For more information visit Heroncode.com Hosted on Acast. See acast.com/privacy for more information.

While some of the technical action is improving in stocks, volume is strikingly missing. Hologic showed a breakout today with decreasing volume and Souther Copper and Alamos Gold got health bounces without volume.

Super STEM Saturday is a free science festival held on March 11, 2023, at California State University San Marcos. Daren Wade is the Director of General Atomics' Aeronautical Systems Integration Group (EIG) and has been involved with the event since 2010. Daren shares how the event engages young engineers and students curious about learning more about how the world works. General Atomics is an event sponsor along with ViaSat, Thermo Fisher Scientific, County of San Diego, Hologic, Encodia, Tri-City Medical Center, Nordson, CalSense, Cox Communications, The Difference Card, Erickson-Hall Construction, Kaiser Permanente, Pacific Western Bank, RBC Capital Markets, Stradling, Young, Minney & Corr, LLP, Cigna, North Island Credit Union, and HME. This free, rain-or-shine event is from 10:00 am-4:00 pm. Learn more here.View the event flyer here

Murthy Simhambhatla launched his medtech career during the epic race to develop groundbreaking drug-eluting stent technologies as a new approach to battling cardiovascular disease. Over two decades later, following a career that took him across the globe and clinical specialities, Simhambhatla finds himself involved in another exciting push to bring new technologies to bear on prevalent medical problems. Simhambhatla leads Setpoint Medical, a trail blazer in the neurostimulation space that's tapping the vagus nerve as way to battle inflammation. In this discussion, we'll cover Simhambhatla's career and how Setpoint is positioned for the future following a significant capital raise. Chris Newmarker, executive editor of life sciences at MassDevice shares his Newmarker's Newsmakers including Avonics, Invacare, Philips, Johnson & Johnson, 3M, Stryker, Edwards, Hologic, BD, Edwards, and Boston Scientific. Thanks for listening to the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast player.

We begin today's show discussing Meta's latest earnings sending shares surging, with insight from our Julia Boorstin and Bernstein analyst Mark Shmulik. Then, Barclays Head of U.S. Equities Venu Krishna to discuss the Fed's latest rate hike, and we preview Apple's results after the bell with CNBC's Steve Kovach and Cowen Managing Director Krish Sankar. Later, our Julia Boorstin returns for a look at TikTok fighting back against regulatory scrutiny, and Hologic CEO Stephen MacMillan joins after the medtech company beat the Street in Q4.

The 2022 WTA season had everything: a 37-match win streak, the retirements of the current #1 (abrupt) and the GOAT (expected), a Wimbledon with no ranking points, and a major drug suspension. Iga Swiatek's dominance didn't leave much room for her competitors, but other highlights included Ons Jabeur's steady rise to world #2 and two Slam runner-up finishes, Caroline Garcia's singles renaissance and WTA Finals title, and utter doubles dominance from Krejcikova/Siniakova. We've also got some juicy listener-generated “things you loved/hated” content and the kind of typically bizarre moments that keep us coming back every year.    Plus, we've just launched our GoFundMe - please read a bit about we do and donate if you can!      0:30 Announcing our GoFundMe 2022 and reiterating our mission 6:05 Three key moments: Ash's Australian win + retirement, Iga's win streak, and Serena's evolution 11:00 The other major stories: the instability at the top for everyone but Iga, Simona Halep's remarkably odd year, and the total breakdown of COVID protocols 18:40 Starting the year with Barty as the undisputed #1 25:20 Ash's retirement coincides with the start of Iga's 37-match win streak  34:45 Grass season: Serena dominates the conversation from Eastbourne to the US Open; Rybakina wins the points-less Wimbledon  42:00 Summer hardcourt stretch: our own return to live tennis; Halep & Garcia grab titles but Swiatek restores order in New York 54:55 Discussing the WTA year-end award nominees 60:45 Our own picks for 2022 breakout players - how'd we do? 63:25 Remember when? A broken necklace, a broken doubles team, and Ostapenko's ... everything 72:45 Things you loved about WTA tennis in 2022 81:50 Things you loathed in 2022: no points at Wimbledon, no more business buns 85:55 The WTA's finances: Hologic sponsorship and a potential deal with private equity 

The Dow surged over 700 points, with all three averages starting Q4 with strong gains, and Jim Cramer is laying out what drove the market higher and if the market's fundamentals can keep the rally going. Then, as Breast Cancer Awareness month kicks off, Cramer sits down with women's health company Hologic. Then, Cramer's digging deeper into recent IPO Permian Resources to see if this Permian basin play could bring profits to your portfolio. Plus, Cramer's exclusive with Agua Media CEO Rick Sanchez.

With so many geopolitical events affecting tennis, it's a timely moment for Catherine to speak at length to WTA CEO Steve Simon. Following yesterday's interview with Pam Shriver, and the decision of Wimbledon and the LTA to ban Russian and Belarusian players, Catherine starts by asking him about those urgent issues. Later, there's discussion about the WTA's decision to pull out of China, Tennis United, the latest on Peng Shuai, new title sponsor Hologic, on court coaching, and the best of 3 vs best of 5 debate at Grand Slams.Sign up to our newsletter - https://bit.ly/TennisPodcastNewsletterFollow us on:Instagram - www.instagram/thetennispodcastTwitter - www.twitter.com/tennispodcastFRIENDS OF THE TENNIS PODCAST Friends of The Tennis Podcast receive exclusive access to bonus podcasts throughout the year and help to keep the weekly podcast and the Grand Slam dailies free-to-all. So far in 2022, we've produced two episodes of Australian Open Re-Lived, an Australian Open review show, three listener Q&A's, and a special 100-minute show dedicated to the career of Juan Martin del Potro. Become a Friend - https://bit.ly/FriendOfTheTennisPodcast See acast.com/privacy for privacy and opt-out information.

As a gynecologist, our guest Dr. Jessica Shepherd has talked with women about their health issues over the last ten years.Most people don't look forward to heading into their doctor's office, or their annual OBGYN exam. Office spaces are often sterile environments, that aren't exactly welcoming. But what if your OBGYN office offered yoga, ayurvedic wellness, nutrition, and more in a calm and pleasant environment. As a healthcare expert, Dr. Shepherd strives to educate people on how to address their physical, sexual, and emotional health. She currently sits on the advisory boards for Ro Medicine, Women's Health Magazine, Abbvie, Myovant, Responsum, Hologic, and HealthyWomen.org. In her Dallas practice, she works with a team of therapists, yoga instructors, Ayurvedic wellness coaches, nutritionists, exercise specialists, and other health professionals dedicated to women's health.Jessica Shepherd MD, MBA, FACOG, is a board-certified OB-GYN and the Chief Medical Officer for Verywell Health. She is the founder and CEO of Sanctum Med + Wellness, a wellness concierge practice, and is affiliated with Baylor University Medical Center in Dallas, Texas.Dr. Shepherd sits down with Dr. Pam to talk about menopause, creating a safe and comforting space for annual OBGYN visits, and how we can continue to make women's health care better, consistent and reliable.

Most people don't look forward to heading into their doctor's office, or their annual OBGYN exam. Office spaces are often sterile environments, that aren't exactly welcoming. But what if your OBGYN office offered yoga, ayurvedic wellness, nutrition, and more in a calm and pleasant environment. As a healthcare expert, Dr. Shepherd strives to educate people on how to address their physical, sexual, and emotional health. She currently sits on the advisory boards for Ro Medicine, Women's Health Magazine, Abbvie, Myovant, Responsum, Hologic, and HealthyWomen.org. In her Dallas practice, she works with a team of therapists, yoga instructors, Ayurvedic wellness coaches, nutritionists, exercise specialists, and other health professionals dedicated to women's health.Jessica Shepherd MD, MBA, FACOG, is a board-certified OB-GYN and the Chief Medical Officer for Verywell Health. She is the founder and CEO of Sanctum Med + Wellness, a wellness concierge practice, and is affiliated with Baylor University Medical Center in Dallas, Texas.Dr. Shepherd sits down with Dr. Pam to talk about menopause, creating a safe and comforting space for annual OBGYN visits, and how we can continue to make women's health care better, consistent and reliable.

The tennis news keeps coming, meaning Catherine, David and Matt have a lot to discuss, including: The WTA's new title sponsor - Hologic - and how it came about from the tour's stance on Peng Shuai and ChinaThe inspirational run of Dayana Yastremska in Lyon just days after she fled Ukraine with her younger sisterThe governing bodies' swift action to stop Russian and Belarusian players from competing under their national flag following a statement from Elina SvitolinaAn absorbing Monterrey final between Leylah Fernandez and Camila Osorio in which both players displayed their best selvesA round up of all the results from this weekend's Davis Cup Qualifiers Djokovic and Vajda split…again, Murray and Lendl get back together…againAsh Barty and Dominic Thiem to miss Indian Wells and Miami An update on Roger Federer's rehab and comeback plansSign up to our newsletter - https://bit.ly/TennisPodcastNewsletterFollow us on:Instagram - www.instagram/thetennispodcastTwitter - www.twitter.com/tennispodcastFRIENDS OF THE TENNIS PODCAST Friends of The Tennis Podcast receive exclusive access to bonus podcasts throughout the year and help to keep the weekly podcast and the Grand Slam dailies free-to-all. So far in 2022, we've produced two episodes of Australian Open Re-Lived, an Australian Open review show, a listener Q&A, and a special 100-minute show dedicated to the career of Juan Martin del Potro. Become a Friend - https://bit.ly/FriendOfTheTennisPodcast See acast.com/privacy for privacy and opt-out information.